Public Companies

Thrive Precision Health – Innovative Healthcare for Diabetics

“We’re building a global diabetes care powerhouse. We’re acquiring established clinics that already specialize in diabetes care and bringing in three cutting-edge technologies to make them even better. Our goal is to provide top-notch care to patients worldwide, with a seamless digital experience. We’re taking healthcare to the next level with groundbreaking technology.

Alvopetro Energy Ltd.’s vision is to become a leading independent upstream and midstream operator in Brazil. Our strategy is to unlock the on-shore natural gas potential in the state of Bahia in Brazil, building off the development of our Caburé and Gomo natural gas projects and the construction of strategic infrastructure assets.

Antibe is a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine. Antibe’s lead drug, ATB-346, targets the global need for a safer non-steroidal anti-inflammatory drug for chronic pain and inflammation. Antibe’s subsidiary, Citagenix Inc., is a leader in the promotion of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix operates in Canada through its direct sales force and internationally via a network of distributors. Antibe is focused on maximizing shareholder value by: (i) growing a portfolio of both pre-approval and commercial assets in the areas of pain, inflammation and regenerative medicine; and (ii) monetizing this portfolio through partnering and commercialization activity.

Apollo Future Mobility Group Limited (ex-WE Solutions Limited) is a Hong Kong-based investment holding company principally engaged in the trading of jewelry products and watches. The Domestic segment is involved in the trading of jewelry products and watches for the retail and wholesale business in the Asia. The Security Investment segment is involved in the trading of listed securities. The Money Lending segment is involved in the provision of loan finance. The Property Investment segment is involved in the investment properties to receive rental income. The Mining segment is involved in the mining, exploration and sale of gold resources. The Electric Vehicle segment is involved in the providing electric vehicle business to business (B2B) solutions, including design, development and assembling of electric vehicles and related auto parts, and providing electric vehicle charging solutions.

AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. Our therapeutic products will be administered to patients as oral non-systemic biologics. The company currently has two products in its pipeline: MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients) and AZX1101, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. The company is headquartered in New York City, with scientific operations in Langlade, France.

Blue Water Ventures International, Inc. (OTC: BWVI) a industry leader in shallow ocean historic shipwreck exploration using archaeologically sound recovery methods which are predicated on state-of-the-art technology targeting shipwrecks primarily in North and Central America as well as the Caribbean.

Canbiola, Inc. is a US Company specializing in the sale of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps, concentrate and water. Canbiola is developing their own line of proprietary products as well as seeking synergistic value through acquisitions in the Hemp Industry.

Cavitation Technologies, Inc. (CTi) is a “GreenTech” development stage company that designs and engineers NANO technology based systems designed to serve growing, global markets such as vegetable oil refining, renewable fuels, petroleum refining,water-fuel emulsions, and food & beverage. CTi’s mission is to improve the environment while helping clients reduce operating costs and increase yield in liquid process applications. CTi’s short-term goal is to commercialize its NANO Neutralization – Systems used to refine vegetable oils derived from oilseeds such as soybeans which are converted into consumer food products. In 2010 we successfully completed pilot testing in a soybean or refining plant. The first commercial licensing of our system occurred in 2010. The system is installed in one vegetable oil refining facility. CTi is in the process of rolling-out the system to the vegetable oil refining industry on a worldwide basis through a global distribution network to a target market of vegetable oil refining plants.

Clean Coal Technologies, Inc. (OTCQB: CCTC) is an emerging growth coal technology company developing what could be the world’s first commercially viable and scalable coal dehydration technology. In 2017, approximately 37% of the world’s energy came from coal. 65% of global coal reserves are sub-bituminous, or low-ranking, and therefore should be upgraded prior to combustion.

Endurance Exploration Group, Inc. (“EXPL”) was incorporated in Nevada in 2006 as Tecton Corporation. In late December 2013, the Company wholly acquired Endurance Exploration Group, LLC and changed the name of the Company to Endurance Exploration Group, Inc. Endurance Exploration Group, LLC was formed in 2009 to research and develop feasibility methodologies to identify, acquire clear title to and ultimately salvage the cargos of shipwrecks.

Fortem Resources Inc. is a junior oil and gas production, development and exploration company with properties located in Western Canada. The Company is engaged in the business of seeking out, evaluating and acquiring working interests in oil and gas projects, domestically and internationally, which it plans to enhance through its management, technical and operational team.

Fortem’s strategy remains focused on developing quality energy projects with lower risk profiles and identified upside potential. The Company will continue to pursue those projects that provide the potential to maximize and grow shareholder value. Fortem operates as Big Lake Energy Ltd. in Alberta and as Fortem Resources Inc. in Saskatchewan. The Company?s common shares trade on the OTC.QB under the symbol FTMR.

H-Source Holdings Ltd. is a technology company operating within the healthcare industry through its wholly owned subsidiary, H-Source, Inc. The Company has developed a transaction platform that provides a private, secure and trusted marketplace for member hospitals to buy, sell and transfer excess inventory supplies and capital equipment with each other. Member hospitals can conduct secure transactions within Integrated Delivery Networks, Group Purchasing Organizations, complete H-Source network or customize their own group hospitals using H-Source’s built-in filters. This marketplace network is specifically designed to reduce health care costs and medical product waste.

Italian Food & Beverage Corp (IFBC) is the owner and direct importer of Dino Luzzi Energy Drink www.dinoluzzi.com and www.ifbcorp.com. The Company has increased its profitability and cash flow with the introduction in 2020 of its brand which is also FDA approved, manufactured in Italy and directly imported in the USA. The Company has launched this year as of April 1st 2022 its energy drink in Italy has well, proud sponsor of the Windsurfer Spring Cup National Regatta taking place in Anzio Italy the 9th and the 10th of April. The Company continues its participation in the Scca Super Hoosier Tour, April 8th 9th and 10 in Virginia this time with two cars #45 and #93, each race can be viewed live stream on https://youtu.be/CxTlagv8NF0 Corporate website www.ifbcorp.com

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), together with its subsidiaries (including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio is highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh, and both a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers (which the company is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet).